Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for<i>Helicobacter pylori</i>eradication: A pilot study

Abstract

Both the 10-day and 14-day therapies were effective as rescue regimens. In particular, the 14-day therapy resulted in successful eradication in over 90% of patients, but the 10-day treatment may be enough to obtain a successful eradication rate, considering the tolerability of therapy.